Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
EHA 2025 – ELVN-001 enlivens investors
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
EHA 2025 – Incyte puts its foot on the CALR gas
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
ASCO 2025 movers – bispecifics to the rescue
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
